ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 860,61
0,14%
DAX
18 726,76
-0,21%
Brent Oil
82,685
-1,01%
Bitcoin
69 723,54
-2,42%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cadrenal Therapeutics Inc (CVKD)

  7. Cadrenal Therapeutics Inc (CVKD) Actualités

CVKD Cadrenal Therapeutics Inc

0,4141
-0,0162 (-3,76%)
Dernière mise à jour : 20:18:43
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Cadrenal Therapeutics Inc CVKD NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0162 -3,76% 0,4141 20:18:43
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,4267 0,4111 0,43 0,4303
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/5/202415:00PRNUSCadrenal Therapeutics Provides First Quarter 2024 Corporate..
09/5/202412:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/4/202422:30PRNUSCadrenal Therapeutics to Participate in Noble Capital..
09/4/202415:00PRNUSCadrenal Therapeutics Receives FDA Orphan Drug Designation..
11/3/202414:15EDGAR2Form 8-K - Current report
11/3/202414:00PRNUSCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate..
05/3/202423:24EDGAR2Form 8-K - Current report
26/2/202415:00PRNUSCadrenal Therapeutics to Participate at Technology and Heart..
15/2/202414:00EDGAR2Form 8-K/A - Current report: [Amend]
12/2/202422:49EDGAR2Form 8-K - Current report
08/2/202415:00PRNUSCadrenal Therapeutics Appoints Jeff Cole as Chief Operating..
31/1/202415:00PRNUSCadrenal Therapeutics Highlights Publication of..
24/1/202415:00PRNUSCadrenal Therapeutics to Participate in a Fireside Chat at..
04/1/202415:00PRNUSCadrenal Therapeutics to Present at the Biotech Showcase on..
19/12/202315:00PRNUSNoble Capital Markets Initiates Coverage on Cadrenal..
12/12/202315:00PRNUSCadrenal Therapeutics Engages The Sage Group to Advance..
30/11/202322:15PRNUSCadrenal Therapeutics to Present at the NobleCon 19..
09/11/202315:15EDGAR2Form 8-K - Current report
09/11/202315:00PRNUSCadrenal Therapeutics Provides Third Quarter 2023 Corporate..
09/11/202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/10/202323:04EDGAR2Form 8-K - Current report
09/10/202322:15PRNUSCadrenal Therapeutics to Participate in the Lytham Partners..
08/9/202322:10EDGAR2Form 8-K - Current report
05/9/202314:00PRNUSCadrenal Therapeutics Highlights Additional Need for a New..
31/8/202322:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
31/8/202322:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/8/202314:00PRNUSCadrenal Therapeutics Expands Evaluation of Tecarfarin for..
28/8/202322:58EDGAR2Form ARS - Annual Report to Security Holders
28/8/202322:55EDGAR2Form DEF 14A - Other definitive proxy statements
28/8/202322:15PRNUSCadrenal Therapeutics to Participate in the H.C. Wainwright..
18/8/202312:06EDGAR2Form 8-K - Current report
16/8/202322:10EDGAR2Form 8-K - Current report
16/8/202322:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/8/202315:16EDGAR2Form 8-K - Current report
10/8/202315:00PRNUSCadrenal Therapeutics Provides Second Quarter 2023 Corporate..
10/8/202312:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202315:00PRNUSCadrenal Therapeutics Expands Focus for Tecarfarin to..
01/8/202312:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
24/7/202315:20EDGAR2Form 8-K - Current report
24/7/202315:15EDGAR2Form S-1 - General form for registration of securities under..
24/7/202315:00PRNUSCadrenal Therapeutics Announces Appointment of Robert..
14/7/202322:52EDGAR2Form 8-K - Current report
14/7/202321:02PRNUSCadrenal Therapeutics Announces Closing of $7.5 Million..
12/7/202321:17PRNUSCadrenal Therapeutics Announces $7.5 Million Private..
01/6/202315:00PRNUSCadrenal Therapeutics to Participate in the 2023 BIO..

Dernières Valeurs Consultées

NASDAQ
CVKD
Cadrenal Therapeutics
LSE
CED2
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés